Mitochondrially targeted ceramides preferentially promote autophagy, retard cell growth, and induce apoptosis

Qi Hou,¹,⁴,† Junfei Jin,¹,†,§ Hui Zhou,† Sergei A. Novgorodov,‡,‡, Alicja Bielawska,† Zdzislaw M. Szulc,§ Yusuf A. Hannun,† Lina M. Obeid,‡,‡,††, and Yi-Te Hsu,²,†

Department of Pharmacology,§ Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P R China; Department of Biochemistry and Molecular Biology,† and Department of Medicine,‡,‡Medical University of South Carolina, Charleston, SC 29425; Research Center of Life Science,§ University of South China, Hengyang, Hunan 421001, P R China; and Ralph H. Johnson Veterans Affairs Medical Center,†† Charleston, SC 29401

Abstract C₆-pyridinium (6′-(1′-pyridinium)-hexanoyl]sphingosine bromide [LCL29]) is a cationic mitochondrial-targeting ceramide analog that promotes mitochondrial permeabilization and cancer cell death. In this study, we compared the biological effects of that compound to those of D-erythro-2-N-[6′-(1′-pyridinium)-hexanoyl]sphingosine bromide [LCL29]) is a cationic mitochondrial-targeting ceramide analog that promotes mitochondrial permeabilization and cancer cell death. In this study, we compared the biological effects of that compound to those of D-erythro-C₆-ceramide, its non-mitochondrion-targeting analog. In MCF7 cells it was found that C₆-pyridinium ceramide preferentially promoted autophagosome formation and retarded cell growth more extensively than its uncharged analog. This preferential inhibition of cell growth was also observed in breast epithelial cells and other breast cancer cells. In addition, this compound could promote Bax translocation to mitochondria. This redistribution of Bax in MCF7 cells could be blocked by the pan-caspase inhibitor zVAD-fmk but via a Bid-independent signaling pathway. Moreover, C₆-pyridinium ceramide-induced translocation of Bax to mitochondria led to mitochondrial permeabilization and cell death. Overall, we show that mitochondrial targeting of C₆-pyridinium ceramide significantly enhances cellular response to this compound.—Hou, Q., J. Jin, H. Zhou, S. A. Novgorodov, A. Bielawska, Z. M. Szulc, Y. A. Hannun, L. M. Obeid, and Y-T. Hsu. Mitochondrially targeted ceramides preferentially promote autophagy, retard cell growth, and induce apoptosis. J. Lipid Res. 2011. 52:278–288.

Supplementary key words ceramide • Bax • mitochondria

Ceramides are bioactive lipids that affect a wide range of biological processes, such as regulation of cellular proliferation, autophagy, and apoptosis (1, 2). Ceramides can be generated through the action of sphingomyelinase or via the de novo synthetic pathway through the action of ceramide synthases (3). Ceramides generated via sphingomyelin hydrolysis can be further hydrolyzed by ceramidases to form sphingosine, which can then be reacylated via the action of ceramide synthases (CerS [also known as LASS]) to regenerate ceramide species. Additions of sphingomyelinase and short-chained C₆-ceramides were shown to inhibit the proliferation of resting T cells (4).

Ceramides also have been shown to induce cellular autophagy, a process utilized to recycle cellular proteins and damaged organelles. Addition of C₆-ceramide resulted in the accumulation of autophagic vesicles in HT-29 colon cancer cells (5). In addition, treatment of MCF7 breast carcinoma cells with the autophagy inducer tamoxifen elevated ceramide production. Tamoxifen-induced autophagy could be inhibited by myriocin, an inhibitor of the de novo pathway of ceramide synthesis (5).

Ceramides are also well-known inducers of apoptosis (6). The resulting apoptotic process appears to involve the proapoptotic protein Bax. Bax is a member of the Bcl-2 family that plays an important role in apoptosis regulation (7). This protein is primarily soluble in healthy cells (8–11). Upon treatment with a variety of apoptotic stimuli, Bax translocates to mitochondria, where it causes the loss

Abbreviations: C₆-pyridinium, 6′-(1′-pyridinium)-hexanoyl]sphingosine bromide; CerS, ceramide synthase; GFP, green fluorescent protein; MEGM, mammary epithelial growth medium; siRNA, short-interfering RNA; TNF-α, tumor necrosis factor α.

This research was supported in part by National Institutes of Health Grants NS-40932 (Y-T. H.) and AG-16583 (L. M. O.) and a MERIT Award (L. M. O.) from the Office of Research and Development, US Department of Veterans Affairs. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or other granting agencies.

Manuscript received 13 October 2010 and in revised form 15 November 2010. Published, JLR Papers in Press, November 16, 2010 DOI 10.1194/jlr.M012161

This article is available online at http://www.jlr.org
of mitochondrial membrane potential (8–11) and the release of cytochrome c from mitochondrial intermembrane spaces (12–15). It has been reported that the addition of exogenous C\textsubscript{6}- and C\textsubscript{16}-ceramides would result in the redistribution of the proapoptotic protein Bax to mitochondria in HL-60 cells and in Bax-transfected DU-145 cells (16). In addition, it has been reported that ultraviolet irradiation could activate sphingomyelinsases, resulting in ceramide upregulation and Bax conformational change in HeLa cells (17). Moreover, it has been shown that expression of mitochondrion-targeting bacterial sphingomyelinase could trigger Bax translocation to mitochondria (18).

Currently, two major apoptotic pathways that signal Bax translocation to mitochondria have been identified (19). In the extrinsic pathway, the binding of death ligands such as FAS and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) to their respective receptors results in the activation of caspase-8. Caspase-8 then cleaves the BH3-only Bid protein, and truncated Bid (tBid) leads to Bax activation and translocation to mitochondria (20–22). In the intrinsic pathway, apoptotic stimuli such as staurosporine and ultraviolet irradiation trigger Bax translocation to mitochondria via mechanisms that are independent of caspase-8 and Bid.

Ceramides can be chemically modified to direct their sequence to a particular cellular compartment. \(\text{d-erythro-2-N-[6'-}(\text{1'}\text{'}\text{'}\text{-pyridinium})\text{-hexanoyl}]\text{sphingosine bromide (LCL29)}\) (C\textsubscript{6}-pyridinium) ceramide is a positively charged analog of the C\textsubscript{6}-ceramide that targets mitochondria and causes mitochondrial permeabilization (23, 24). Its \(\text{L-threo}\) isomer (LCL124) has displayed a potent antitumor effect in human head and neck squamous cell carcinomas (25). As C\textsubscript{6}-pyridinium ceramide elicits a number of the above-mentioned biological effects, it is unclear how the mitochondrial targeting of this compound will affect its potency. Here, we show that this positively charged ceramide, compared with its neutral counterpart, elicits enhanced efficiency in regulating various cellular processes in MCF7 cells, including cellular growth, autophagy, and apoptosis. In addition, we show that C\textsubscript{6}-pyridinium ceramide-induced cell death involves Bax redistribution, independently of Bid.

### MATERIALS AND METHODS

#### Materials

MCF7, MCF10A, MDA-MB-157, and MDA-MB-231 cells were obtained from American Type Culture Collection. LysoTracker Red, fetal bovine serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM), and tissue culture supplements were from Invitrogen, Inc. FuGENE 6 transfection reagent was from Roche, and Maxiprep kits were from Qiagen. Horseradish peroxidase- and Cy3-conjugated secondary immunoglobulins and enhanced chemiluminescence (ECL) Western blotting detection kit were obtained from Amersham. Anti-Bid and cytochrome c antibodies were from BD Pharmingen. Anti-LC3 antibody was from Santa Cruz Biotechnology. Human LC3 TruClone cDNA was purchased from Origene. Pan-caspase inhibitor zVAD-fmk and a mammmary epithelial growth medium (MEGM) kit were purchased from Lonza Corp. Oligonucleotides and transfection reagents used in short-interfering RNA (siRNA) studies were purchased from Dharmacon. A mitochondria isolation kit was from Pierce. All other chemicals were from either Sigma or Fisher Scientific. C\textsubscript{6}-pyridinium ceramide (LCL29) and C\textsubscript{6}-ceramide were synthesized by the Lipidomics Core facility at Medical University of South Carolina as previously described and were dissolved in dimethyl sulfoxide (24).

#### Cell culturing

MCF7, MDA-MB-157, and MDA-MB-231 cells were cultured in DMEM supplemented with 10% FBS. MCF10A cells were cultured by using a MEGM kit supplemented with 10% FBS. All cells were maintained in 5% CO\textsubscript{2} at 37°C.

#### Development of MCF7 cells stably expressing green fluorescent protein-LC3

Human LC3 cDNA was amplified by PCR and cloned into HindIII and EcoRI sites of the LC3-EGFP vector (GFP-LC3). To develop stable clones of MCF7 cells expressing GFP-LC3, MCF7 cells were seeded onto 10 cm plates and cultured in DMEM supplemented with 10% FBS. Cells were transfected with 12 \(\mu\)g of C3-GFP-LC3 plasmid with FuGENE transfection reagent. The day after transfection, cells were selected with 0.2 mg/ml G418. After a week of selection, GFP-positive cells were sorted by flow cytometry and maintained in DMEM culture medium in the presence of 0.2 mg/ml G418.

#### MTT and Trypan blue exclusion assays

Cell growth assay was determined by using an in vitro 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)-based assay kit according to the manufacturer’s instructions. Briefly, MCF7, MCF10A, MDA-MB-157, and MDA-MB-231 cells were seeded onto 6-well plates at a density of 6 \(\times\) 10\textsuperscript{4} cells/ml. After 24 h, cells were incubated with different concentrations of C\textsubscript{6}-pyridinium ceramide or C\textsubscript{6}-ceramide for specified times. The IC\textsubscript{50} of each compound was determined from cell growth plots (26). For Trypan blue exclusion assay, MCF7 cells were plated onto 6-well plates (1 \(\times\) 10\textsuperscript{6} cells/plate) and then treated with 10 \(\mu\)M C\textsubscript{6}-pyridinium ceramide or C\textsubscript{6}-ceramide for specified times. Cells were then collected and mixed 1:1 (v/w) with Trypan blue dye. Cells that excluded the dye were counted.

#### Induction of apoptosis by TNF-\(\alpha\), staurosporine, and C\textsubscript{6}-pyridinium ceramide

MCF7 or GFP-Bax stable MCF7 cells were plated onto 6-well plates. Cells were then treated with TNF-\(\alpha\), staurosporine, cetylpyridinium bromide, C\textsubscript{6}-ceramide, or C\textsubscript{6}-pyridinium ceramide. After specified times, cells were either visualized with fluorescence microscopy or subjected to immunofluorescence labeling with anti-Bid or anti-cytochrome c antibody. Subcellular fractionation to prepare cytosolic and heavy membrane fractions from cells treated with these agents was carried out using a mitochondria isolation kit according to the manufacturer’s protocol. Resulting protein samples were analyzed by Western blotting with an anti-Bax antibody. To visualize colocalization of Bax with mitochondria, MCF7 cells stably expressing GFP-Bax and mitochondrion-targeted red fluorescent protein (DS-red-mito; 27) were treated with the ceramides for 18 h and then visualized with fluorescence microscopy.

#### Immunofluorescence labeling and fluorescence microscopy

For immunofluorescence labeling, MCF7 cells were plated onto 6-well plates. Cells were subjected to apoptosis induction with the above-stated agents, in the presence or absence of 50 \(\mu\)M zVAD-fmk, for specified time periods. Both treated and untreated
cells were then washed three times in phosphate-buffered saline (PBS), fixed in 6% paraformaldehyde for 30 min, and permeabilized with a 0.06% saponin solution in PBS for 15 min. Cells were subsequently blocked for 30 min in the blocking buffer containing PBS, 5% FBS, and a 0.06% saponin mixture. Cells were then incubated with 5 μg/ml anti-Bid, or 5 μg/ml anti-cytochrome c antibody diluted in blocking buffer containing a 0.04% saponin mixture for 2 h. Cells were then washed and incubated with 6 μg/ml Cy3-labeled goat anti-rabbit or goat anti-mouse immunoglobulin in the blocking buffer containing a 0.04% saponin solution for an additional 2 h. Cells were then washed with PBS and treated with the antifade reagent. Cells were visualized with an Olympus IX-70 fluorescence microscope using an LCPlanFI 20× objective lens at 1.5× intermediate magnification. Images were acquired with an Optronics DEI-750D digital imaging camera.

**Induction of autophagy by ceramide**

For LysoTracker staining studies, GFP-Bax stable MCF7 cells were plated onto 6-well plates. Cells were then incubated with 10 μM C6-pyridinium ceramide or C6-ceramide for 16 h. Cells were then stained with 0.75 μM LysoTracker Red for 30 min and visualized with an Olympus IX-70 fluorescence microscope. To visualize autophagosome formation, GFP-LC3 stable MCF7 cells were plated onto 6-well plates, treated with C6-pyridinium ceramide or C6-ceramide for 16 h, and visualized by fluorescence microscopy. For assessment of the LC3-II-to-LC3-I ratio by immunoblotting, cells were treated with 10 μM C6-pyridinium ceramide or C6-ceramide for 18 h. Cell lysates were then analyzed by Western blotting with an anti-LC3 antibody. To determine the level of Beclin-1 in the cell lysates, Western blotting analysis with an anti-Beclin-1 antibody was carried out. The expression level of Beclin-1 was normalized to that of β-actin, using a Scion image program.

**SDS-PAGE and Western blotting**

SDS-PAGE (12%) and Western blotting analyses were carried out as previously described (28). For immunoblotting analysis, blots were probed with anti-Bax, Bcl-2, and Bcl-XL (1:10 dilution culture fluid) (9, 28), ATP-synthase β-subunit 9D7 (1:10 dilution culture fluid), anti-Bid (1 μg/ml), anti-LC3 (1 μg/ml), anti-Beclin-1 (1 μg/ml), or anti-β-actin (1 μg/ml) antibody. Immunoblotting and ECL documentation were carried out as previously described (28).

**RESULTS**

**C6-pyridinium ceramide preferentially mediates autophagy in MCF7 cells**

Elevation in ceramide levels has been attributed to an elevation in cellular autophagy (5). To determine the efficacy of short-chained ceramides in promoting autophagosome formation, we treated MCF7 cells with either C6-ceramide or C6-pyridinium ceramide for 16 h. Cells were then stained with LysoTracker Red and visualized by fluorescence microscopy. As shown in Fig. 1A, a number of cells treated with C6-pyridinium ceramide displayed LysoTracker Red-stained vesicles. On the other hand, untreated and C6-ceramide-treated cells showed far fewer stained vesicles. In addition, MCF7 cells stably expressing GFP-LC3 were generated. Cells were then treated with the above-stated compounds for 16 h and visualized by fluorescence microscopy. As shown in Fig. 1B, the cells treated with the positive control tamoxifen displayed numerous GFP-labeled autophagosome vesicles. Similarly, cells treated with C6-pyridinium ceramide had numerous autophagosome vesicles, albeit fewer than the tamoxifen-treated cells. On the other hand, in untreated and C6-ceramide-treated cells, GFP-LC3 remained primarily in the cytoplasm.

In addition, Western blotting analysis of cell lysates was carried out to determine the LC3-II-to-LC3-I ratio, which serves as an indicator of autophagosome formation. As shown in Fig. 2A, upon treatment with C6-pyridinium ceramide or tamoxifen, there was an obvious increase in the LC3-II-to-LC3-I ratio, compared with that in untreated and C6-ceramide-treated cells. We also examined the lysates from MCF10A breast epithelial cells, MDA-MB-137 medullary carcinoma, and MDA-MB-231 breast adenocarcinoma cells. Interestingly, both of the treatments with C6-ceramide and C6-pyridinium ceramide resulted in an increase in the LC3-II-to-LC3-I ratio in MDA-MB-231 cells. No LC3 was detected in MCF10A and MDA-MB-137 cell lysates. Moreover, the level of Beclin-1 in MCF7 cells following ceramide treatment was also examined. We found that treatment with C6-pyridinium ceramide did not appreciably increase the level of Beclin-1 (Fig. 2B, C).

**C6-pyridinium ceramide inhibits cell growth and promotes cell death**

To assess the effects of C6-pyridinium ceramide and C6-ceramide on cell growth, MCF7 cells were treated with different concentrations of these compounds. At 24 h posttreatment,
C₆-pyridinium ceramide-mediated cellular effects

The IC₅₀ of these compounds were found to be 52 µM, 4 µM, and 48 µM, respectively, for the above-listed cells. On the other hand, the growth of these cells remained static following C₆-ceramide treatment. We also monitored cell growth inhibition over time in the presence of 10 µM of these compounds. As shown in Fig. 4B, cell growth inhibition and most likely a decrease in cell viability were evident over time for all three cell lines upon C₆-pyridinium ceramide treatment, compared with that with C₆-ceramide treatment.

In addition to examining effects on MCF7 cells, we also compared the effects of these two compounds on the growth of MCF10A, MDA-MB-157, and MD-MB-231 cells by using the MTT assay. Figure 4A shows that increasing concentrations of C₆-pyridinium ceramide significantly enhanced the inhibition of cell growth. The IC₅₀ of these compounds were found to be 52 µM, 4 µM, and 48 µM, respectively, for the above-listed cells. On the other hand, the growth of these cells remained static following C₆-ceramide treatment. We also monitored cell growth inhibition over time in the presence of 10 µM of these compounds. As shown in Fig. 4B, cell growth inhibition and most likely a decrease in cell viability were evident over time for all three cell lines upon C₆-pyridinium ceramide treatment, compared with that with C₆-ceramide treatment.

Fig. 2. C₆-pyridinium ceramide (C₆-Pyr-Cer) elevates the ratio of LC3-II/LC3-I without markedly changing the level of Beclin-1. A: MCF7 and MDA-MB-231 cells were treated with 10 µM C₆-ceramide (C₆-Cer), 10 µM C₆-pyridinium ceramide, or 50 µM tamoxifen (TAM), for 16 h. Cell lysates from untreated (lanes a), C₆-ceramide- (lanes b), C₆-pyridinium ceramide- (lanes c), or tamoxifen-treated (lanes d) cells were analyzed by Western blotting with anti-LC3. The positions of LC3-I and LC3-II forms are indicated. B: MCF7 cells lysates from the above treatment were analyzed by Western blotting with anti-Beclin 1 and β-actin antibodies. C: The relative expression levels of Beclin-1 from different treatments were normalized to β-actin and compared with the control untreated sample. Results were averaged from three independent studies.

Fig. 3. C₆-pyridinium ceramide (C₆-Pyr-Cer) inhibited MCF7 cell growth in a dose- and time-dependent manner. MCF7 cells were plated onto 6-well plates and treated with different concentrations (0–80 µM) of C₆-pyridinium ceramide or C₆-ceramide (C₆-Cer) for 24 h (A), or with 10 µM of these compounds for various time periods (B). At specified time points, MTT assays were performed. Time-course results were normalized to values from the control cells at the initial time point. C: Control MCF7 cells and cells treated with 10 µM C₆-ceramide or C₆-pyridinium ceramide were collected and stained with Trypan blue to determine the number of live cells at different time points. All results were averaged from three independent studies. Values are means ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus the control.

Fig. 4. Effects of C₆-pyridinium ceramide (C₆-Pyr-Cer) on cellular proliferation and apoptosis. A: MCF7 and MDA-MB-231 cells were treated with 10 µM C₆-ceramide (C₆-Cer), 10 µM C₆-pyridinium ceramide, or 50 µM tamoxifen (TAM), for 16 h. Cell lysates from untreated (lanes a), C₆-ceramide- (lanes b), C₆-pyridinium ceramide- (lanes c), or tamoxifen-treated (lanes d) cells were analyzed by Western blotting with anti-LC3. The positions of LC3-I and LC3-II forms are indicated. B: MCF7 cells lysates from the above treatment were analyzed by Western blotting with anti-Beclin 1 and β-actin antibodies. C: The relative expression levels of Beclin-1 from different treatments were normalized to β-actin and compared with the control untreated sample. Results were averaged from three independent studies.
Because Bax can induce mitochondrial permeabilization, we therefore set out to determine the role of this protein in C₆-pyridinium ceramide-mediated cell killing. A key step by which Bax promotes cell death involves its translocation from the cytoplasm to mitochondria (10, 11). In order to enable a rapid assessment of Bax subcellular localization, we used MCF7 breast carcinoma cell line stably expressing GFP-Bax (27).

Fluorescence microscopy analysis indicated that under nonapoptotic conditions, in greater than 98% of the cells Bax was localized to the cytoplasm and that in fewer than 2% of the cells Bax was localized to mitochondria. We found that when these cells were subjected to apoptosis induction with a variety of agents including the extrinsic pathway inducer TNF-α (10 ng/ml for 16 h), the intrinsic pathway inducer staurosporine (0.2 μM for 6 h), or C₆-pyridinium ceramide (10 μM for 16 h), there was a shift in the fluorescence pattern of GFP-Bax from a diffuse cytoplasmic state to a punctate membrane-bound state (Fig. 6A).

On the other hand, GFP-Bax remained cytoplasmic in cells treated with C₆-ceramide or cetylpyridinium bromide (both, 10 μM for 16 h). To verify that punctate GFP-Bax localized with mitochondria, GFP-Bax-stable and Ds-red-mito-stable MCF7 cells were treated with C₆-ceramide or C₆-pyridinium ceramide and then visualized by fluorescence microscopy. As shown in Fig. 6B, punctate GFP-Bax colocalizes with DS-red-mito-labeled mitochondria. These results indicate that C₆-pyridinium ceramide, which localizes to mitochondria, induces Bax translocation to mitochondria.

To determine the time course of C₆-pyridinium ceramide-mediated Bax translocation to mitochondria, GFP-Bax-stable MCF7 cells were treated with 10 μM of this compound for various periods of time (Fig. 7A). We also treated cells with different concentrations of either C₆-ceramide or C₆-pyridinium ceramide for 18 h and quantitated the extent of GFP-Bax localization to mitochondria by fluorescence microscopy (Fig. 7B). Results showed that increasing concentrations of C₆-pyridinium ceramide

As C₆-pyridinium ceramide treatment induces cell death as well as autophagy, we then examined whether inhibition or promotion of autophagy enhances cell survival. MCF7 cells were treated with the autophagy inhibitor 3-methyl adenine or the autophagy promoter tamoxifen, in the presence or absence of C₆-pyridinium ceramide for 24 h. Cells were then stained with Hoechst dye to detect apoptotic nuclei. As shown in Fig. 5, the presence of tamoxifen reduced the number of apoptotic nuclei following C₆-pyridinium ceramide treatment. This result suggests that in MCF7 cells, autophagy may serve as a protective mechanism against C₆-pyridinium ceramide-mediated mitochondrial damage.

C₆-pyridinium ceramide, but not C₆-ceramide, induces Bax translocation from the cytoplasm to mitochondria in MCF7 cells

C₆-pyridinium ceramide has been previously shown to be a potent anticancer agent that mediates mitochondrial permeabilization and cell death (23). Because Bax can induce mitochondrial permeabilization, we therefore set out to determine the role of this protein in C₆-pyridinium ceramide-mediated cell killing. A key step by which Bax promotes cell death involves its translocation from the cytoplasm to mitochondria (10, 11). In order to enable a rapid assessment of Bax subcellular localization, we used MCF7 breast carcinoma cell line stably expressing GFP-Bax (27).

Fluorescence microscopy analysis indicated that under nonapoptotic conditions, in greater than 98% of the cells Bax was localized to the cytoplasm and that in fewer than 2% of the cells Bax was localized to mitochondria. We found that when these cells were subjected to apoptosis induction with a variety of agents including the extrinsic pathway inducer TNF-α (10 ng/ml for 16 h), the intrinsic pathway inducer staurosporine (0.2 μM for 6 h), or C₆-pyridinium ceramide (10 μM for 16 h), there was a shift in the fluorescence pattern of GFP-Bax from a diffuse cytoplasmic state to a punctate membrane-bound state (Fig. 6A).

On the other hand, GFP-Bax remained cytoplasmic in cells treated with C₆-ceramide or cetylpyridinium bromide (both, 10 μM for 16 h). To verify that punctate GFP-Bax localized with mitochondria, GFP-Bax-stable and Ds-red-mito-stable MCF7 cells were treated with C₆-ceramide or C₆-pyridinium ceramide and then visualized by fluorescence microscopy. As shown in Fig. 6B, punctate GFP-Bax colocalizes with DS-red-mito-labeled mitochondria. These results indicate that C₆-pyridinium ceramide, which localizes to mitochondria, induces Bax translocation to mitochondria.

To determine the time course of C₆-pyridinium ceramide-mediated Bax translocation to mitochondria, GFP-Bax-stable MCF7 cells were treated with 10 μM of this compound for various periods of time (Fig. 7A). We also treated cells with different concentrations of either C₆-ceramide or C₆-pyridinium ceramide for 18 h and quantitated the extent of GFP-Bax localization to mitochondria by fluorescence microscopy (Fig. 7B). Results showed that increasing concentrations of C₆-pyridinium ceramide

As C₆-pyridinium ceramide treatment induces cell death as well as autophagy, we then examined whether inhibition or promotion of autophagy enhances cell survival. MCF7 cells were treated with the autophagy inhibitor 3-methyl adenine or the autophagy promoter tamoxifen, in the presence or absence of C₆-pyridinium ceramide for 24 h. Cells were then stained with Hoechst dye to detect apoptotic nuclei. As shown in Fig. 5, the presence of tamoxifen reduced the number of apoptotic nuclei following C₆-pyridinium ceramide treatment. This result suggests that in MCF7 cells, autophagy may serve as a protective mechanism against C₆-pyridinium ceramide-mediated mitochondrial damage.

C₆-pyridinium ceramide, but not C₆-ceramide, induces Bax translocation from the cytoplasm to mitochondria in MCF7 cells

C₆-pyridinium ceramide has been previously shown to be a potent anticancer agent that mediates mitochondrial permeabilization and cell death (23). Because Bax can induce mitochondrial permeabilization, we therefore set out to determine the role of this protein in C₆-pyridinium ceramide-mediated cell killing. A key step by which Bax promotes cell death involves its translocation from the cytoplasm to mitochondria (10, 11). In order to enable a rapid assessment of Bax subcellular localization, we used MCF7 breast carcinoma cell line stably expressing GFP-Bax (27).

Fluorescence microscopy analysis indicated that under nonapoptotic conditions, in greater than 98% of the cells Bax was localized to the cytoplasm and that in fewer than 2% of the cells Bax was localized to mitochondria. We found that when these cells were subjected to apoptosis induction with a variety of agents including the extrinsic pathway inducer TNF-α (10 ng/ml for 16 h), the intrinsic pathway inducer staurosporine (0.2 μM for 6 h), or C₆-pyridinium ceramide (10 μM for 16 h), there was a shift in the fluorescence pattern of GFP-Bax from a diffuse cytoplasmic state to a punctate membrane-bound state (Fig. 6A).

On the other hand, GFP-Bax remained cytoplasmic in cells treated with C₆-ceramide or cetylpyridinium bromide (both, 10 μM for 16 h). To verify that punctate GFP-Bax localized with mitochondria, GFP-Bax-stable and Ds-red-mito-stable MCF7 cells were treated with C₆-ceramide or C₆-pyridinium ceramide and then visualized by fluorescence microscopy. As shown in Fig. 6B, punctate GFP-Bax colocalizes with DS-red-mito-labeled mitochondria. These results indicate that C₆-pyridinium ceramide, which localizes to mitochondria, induces Bax translocation to mitochondria.

To determine the time course of C₆-pyridinium ceramide-mediated Bax translocation to mitochondria, GFP-Bax-stable MCF7 cells were treated with 10 μM of this compound for various periods of time (Fig. 7A). We also treated cells with different concentrations of either C₆-ceramide or C₆-pyridinium ceramide for 18 h and quantitated the extent of GFP-Bax localization to mitochondria by fluorescence microscopy (Fig. 7B). Results showed that increasing concentrations of C₆-pyridinium ceramide
10% in the presence of zVAD-fmk, indicative of a direct role of caspase in TNF-α-mediated Bax translocation to mitochondria. On the other hand, the addition of zVAD-fmk had no effect on staurosporine-mediated Bax translocation. As for C<sub>e</sub>-pyridinium ceramide, the addition of zVAD-fmk significantly decreased Bax translocation to mitochondria (Fig. 8A, B). In addition to using fluorescence microscopy, we carried out subcellular fractionation of control and treated cells. As shown in Fig. 8C, TNF-α, staurosporine, and C<sub>e</sub>-pyridinium ceramide resulted in a shift in Bax (both GFP-tagged and endogenous) distribution from the cytosolic to mitochondrial fraction. Incubation of cells with zVAD-fmk significantly inhibited Bax redistribution to mitochondria. Therefore, caspases appear to be involved in the action of both agents on Bax.

To determine the role of Bid in C<sub>e</sub>-pyridinium ceramide-mediated Bax translocation to mitochondria, GFP-Bax-stable MCF7 cells were treated with this compound either in the presence or absence of zVAD-fmk, and the treated cells were then subjected to immunofluorescence labeling with an anti-Bid antibody. For comparison, we also treated cells with 10 ng/ml TNF-α or 0.2 μM staurosporine. As shown in increased the percentage of cells in which Bax was localized to mitochondria. On the other hand, we found that non-mitochondrion-targeting C<sub>e</sub>-ceramide had little effect on promoting Bax translocation to mitochondria.

**C<sub>e</sub>-pyridinium ceramide induces Bax translocation from the cytoplasm to mitochondria via a caspase-dependent and Bid-independent manner**

In order to examine the signaling pathway leading to Bax translocation to mitochondria in GFP-Bax-stable MCF7 cells treated with C<sub>e</sub>-pyridinium ceramide, we first examined whether this translocation process was caspase dependent by the addition of the pan-caspase inhibitor zVAD-fmk. For verification of efficacy and specificity, cells were also treated with TNF-α or staurosporine in the presence or absence of zVAD-fmk. As shown in Fig. 8A and B, in the absence of zVAD-fmk, treatment with TNF-α resulted in approximately 90% of cells had Bax localized to mitochondria. In contrast, the percentage of GFP-Bax punctate cells in response to TNF-α was greatly reduced to...
or C₆-pyridinium ceramide-mediated Bax redistribution. Overall, these results indicate that C₆-pyridinium ceramide-mediated Bax translocation to mitochondria in MCF7 cells is dependent on a caspase but independent of Bid.

C₆-pyridinium ceramide-induced Bax translocation leads to cytochrome c release and cell death

Previously, it has been shown that Bax translocation to mitochondria leads to the release of cytochrome c (14, 31, 32) and cell death. By using immunofluorescence labeling with an anti-cytochrome c antibody, we found that in healthy cells, where GFP-Bax was cytoplasmic, cytochrome c was retained in mitochondria (Fig. 10A). On the other hand, cytoplasmic cytochrome c became evident in TNF-α/H9251-, staurosporine-, and C₆-pyridinium ceramide-treated cells that had GFP-Bax localized to mitochondria. In addition, by staining both the untreated and treated cells with Hoechst nuclear stain, we found that there was significant cell death, as evidenced by nuclear condensation in cells that had GFP-Bax localized to mitochondria. In summary, these results indicate that C₆-pyridinium ceramide-mediated mitochondrial permeabilization and cell death involve Bax.

DISCUSSION

C₆-pyridinium ceramide was developed as a positively charged ceramide that preferentially accumulates in mi-
C_{6}-pyridinium ceramide-mediated cellular effects preferentially promotes cellular autophagy, retards cell growth, and induces cellular apoptosis.

Short-chained ceramides have been shown to promote cellular autophagy (5). In the current study, we show that mitochondria of living cells (23). In this report, we compared the biological effects of this mitochondrion-targeting C_{6}-ceramidoid to its neutral non-mitochondrion-targeting analog. We found that this positively charged ceramide preferentially promotes cellular autophagy, retards cell growth, and induces cellular apoptosis.

Short-chained ceramides have been shown to promote cellular autophagy (5). In the current study, we show that

Fig. 9. Bid is not involved in C_{6}-pyridinium ceramide-(C_{6}-Pyr-Cer) mediated Bax translocation to mitochondria. A: MCF7 cells stably expressing GFP-Bax were treated with 10 ng/ml TNF-\(\alpha\) (18 h), 0.2 \(\mu\)M staurosporine (STS) (6 h), or 10 \(\mu\)M C_{6}-pyridinium ceramide (18 h) either in the absence or presence of \(z\)VAD-fmk. Cells were then subjected to immunofluorescence labeling with an anti-Bid antibody. Labeled cells were visualized by fluorescence microscopy. B: GFP-Bax-stable MCF7 cells were treated with various apoptosis inducing agents (TNF-\(\alpha\), staurosporine, C_{6}-pyridinium ceramide) in the presence or absence of \(z\)VAD-fmk. Cell lysates prepared from untreated and treated cells were analyzed by Western blotting with an anti-Bid antibody. C: GFP-Bax-stable MCF7 cells were transfected with either scrambled, nonsilencing siRNA or Bid siRNA oligonucleotides for 64 h. Cell lysates from untransfected (lane a), scrambled siRNA (lane b), and Bid siRNA (lane c) oligonucleotide transfected cells were then analyzed by Western blotting with anti-Bid, Bcl-2, and ATP synthase \(\beta\)-subunit antibodies. D. MCF7 cells stably expressing GFP-Bax were transfected with either scrambled siRNA or Bid siRNA oligonucleotide for 48 h. Cells were then treated with 10 ng/ml TNF-\(\alpha\) (18 h), 0.2 \(\mu\)M staurosporine (6 h), or 10 \(\mu\)M C_{6}-pyridinium ceramide (18 h). Cells were subsequently visualized by fluorescence microscopy and the percentages of GFP-Bax punctate cells were quantitated from four separate visual fields. The study was carried out three times.

Fig. 10. Bax localization to mitochondria in GFP-Bax-stable MCF7 cells is associated with the release of cytochrome c (Cyt. c) and nuclear condensation. A: GFP-Bax-stable MCF7 cells were treated with 10 ng/ml TNF-\(\alpha\) (18 h), 0.2 \(\mu\)M staurosporine (STS) (6 h), or 10 \(\mu\)M C_{6}-pyridinium ceramide (C_{6}-Pyr-Cer) (18 h). Untreated and treated cells were then subjected to immunofluorescence labeling with an anti-cytochrome c antibody and visualized by fluorescence microscopy. B: GFP-Bax-stable MCF7 cells were treated with the above-stated apoptotic stimuli. Cells were then stained with Hoechst nuclear stain and visualized by fluorescence microscopy.
C₆-pyridinium ceramide treatment of MCF7 cells significantly enhanced the production of acidic vesicular organelles and autophagosomes and elevated the level of LC3-II. On the other hand, no significant formation of acidic vesicular organelles, autophagosomes, or LC3-II was observed in C₆-ceramide-treated MCF7 cells. Interestingly, formation of LC3-II was observed in MDA-MB-231 cells treated with C₆-ceramide. This suggests that the formation of autophagosomes induced by short-chained ceramide may be cell-type dependent. Moreover, upregulation of Beclin-1 has been suggested as a mechanism by which ceramide promotes autophagy (5). However, in our study, we did not observe a ceramide-induced elevation in Beclin-1. Alternatively, it is possible that ceramide may enhance JNK1-dependent Bcl-2 phosphorylation to enable its dissociation from Beclin-1 to promote autophagy (33).

Autophagy has been proposed to act either as a tumor suppressor to promote cancer cell death or as a cytoprotective mechanism to shield cancer cells against anticancer treatments (34). In our study, we found that treatment of MCF7 cells with the autophagy promoter tamoxifen could attenuate C₆-pyridinium ceramide-mediated cell death, suggesting that autophagy may represent a cellular protective mechanism. In addition, we found that this compound induced autophagy within the same time frame as apoptotic cell death in MCF7 cells. In our study, we found that the pan-caspase inhibitor zVAD-fmk could attenuate C₆-pyridinium ceramide-mediated Bax redistribution and cell death but not autophagosome formation (data not shown). Either these two events are independent of each other or autophagosome formation is upstream of the zVAD-fmk-sensitive portion of the Bax-activation signaling pathway. Interestingly, Akt activation has been shown to suppress apoptosis and autophagy (35, 36), and a ceramide could suppress Akt activity though activation of protein phosphatase 2 than C₆-ceramide to promote both apoptosis and autophagy.

Previously, it has been reported that C₆-pyridinium ceramide can attenuate the proliferation of resting T cells (4). In the current study, it was shown that C₆-pyridinium ceramide could greatly reduce the rate of cell growth compared with its uncharged analog in breast epithelial and breast cancer cell lines, with higher IC₅₀ values in breast epithelial cells than in cancer cells. The accumulation of C₆-pyridinium ceramide in mitochondria and its ability to promote mitochondrial permeabilization (23) likely reduced mitochondrial function and cell viability, thus contributing to the observed decrease in the rate of cell growth.

Currently, two main apoptotic signaling pathways have been proposed that regulate Bax translocation to mitochondria. In the extrinsic pathway of apoptosis, caspase-8 cleaved Bid activates Bax and leads to Bax translocation to mitochondria. On the other hand, in the intrinsic pathway of apoptosis, Bax activation and mitochondrial translocation are independent of caspase-8 and Bid. In this study, we have uncovered a unique Bax-activating process mediated by C₆-pyridinium ceramide in MCF7 cells that is dependent on a caspase but independent of Bid.

Previously, it was reported that C₆-pyridinium ceramide could induce mitochondrial permeabilization (23). Based on the current study, it is likely that this permeabilization is mediated through Bax translocation to mitochondria, causing the release of apoptogenic proteins such as cytochrome c. In addition, it has been shown that addition of C₆- and C₆-ceramide could cause a Bax conformational change and localization to mitochondria (16, 39–41). Fluorescently labeled short-chain ceramide species have been shown to be localized to the Golgi apparatus (23, 42). Surprisingly, in our study, we found that C₆-ceramide had little effect in triggering Bax translocation, even at high concentrations. This difference may be due to the different cell types used and the method of detecting Bax translocation. Alternatively, it may be possible that C₆-ceramide also reaches mitochondria; however, the local concentrations are either lower or it is metabolized differently than C₆-pyridinium ceramide. Interestingly, we found that addition of cetylpyridinium bromide did not promote Bax translocation, suggesting that the pyridinium moiety of the C₆-pyridinium ceramide, although important for targeting to mitochondria, is not responsible for Bax activation.

It was recently reported that d-threo-sphingosine could promote Bax activation in rhabdomyosarcoma cells (43). This effect appeared to be stereo-specific as its l-threo and d,l-threo analogs were ineffective at inducing cell death. We have tested l-threo- and d-threo-C₆-pyridinium ceramides (LCL187 and LCL124, respectively) and found them to be equally effective at triggering Bax translocation to mitochondria (Hou et al., unpublished data). This suggests that stereochernistry of C₆-pyridinium ceramide is not critical in regulating Bax translocation.

Bax undergoes a conformational change as it redistributes to mitochondria (44). It has been previously shown that Bax conformational change could be induced by nonionic detergents (9, 28). In our study, we found that incubation of soluble Bax with C₆-pyridinium ceramide did not lead to a conformational change (Hou and Hsu, data not shown). This suggests that Bax activation is a consequence of the signaling event initiated by this mitochondrion-targeting ceramide rather than a direct alteration of Bax conformation by this compound.

In the TNF-α-mediated apoptotic pathway, activation of caspase-8 causes Bid cleavage. (Bid then translocates to mitochondria and activates Bax. In our GFP-Bax-stable MCF7 cells, we also observed this TNF-α-mediated Bid cleavage and the cotranslocation of Bid and Bax to mitochondria. This is in contrast with the staurosporine-induced apoptotic pathway in which we observed Bax translocation to mitochondria in the absence of Bid cleavage and mitochondrial translocation. On the other hand, we found that C₆-pyridinium ceramide triggered Bax translocation to mitochondria via a caspase-dependent pathway but without Bid cleavage and without colocalization to mitochondria. Consistently, we found that knockdown of Bid by the siRNA approach attenuated Bax translocation in TNF-α but not in staurosporine- or C₆-pyridinium ceramide-treated cells.
TNF-α has been previously shown to elevate ceramide production in HL-60 and A431 cells (45, 46). It remains to be determined to what extent this elevated pool of ceramide contributes to Bax activation.

It has been reported that ceramides derived from acid sphingomyelinase in the lysosome could activate cathepsin D (47), which in turn, could lead to Bax activation by an as-yet-unknown mechanism (48). We found that pepstatin A, which has been reported to inhibit cathepsin D and Bax activation in staurosporine-treated T lymphocytes, had no effect in influencing Bax localization in C6-pyridinium ceramide- or staurosporine-treated MCF7 cells (Hou and Hsu, unpublished observation). This suggests that Bax translocation induced by C6-pyridinium ceramide in MCF7 cells likely does not involve cathepsin D and may be distinct from the lysosomal pathways mediated by ceramide.

In MCF7 cells, we found that C6-pyridinium ceramide-mediated Bax redistribution appeared to be caspase-dependent. Further analysis with various caspase inhibitors indicated that the caspase-3 inhibitor Z-WEHD-fmk could also significantly inhibit Bax redistribution (Hou and Hsu, unpublished data). Although this caspase-dependent signaling pathway appeared to be important for Bax redistribution, it is unique, however, only to MCF7 cells. We found that in DU-145, NT-2, LS-180, and DLD cells stably expressing GFP-Bax, addition of zVAD-fmk did not attenuate C6-pyridinium ceramide-mediated Bax redistribution (Hou and Hsu, unpublished data).

Overall, our study shows that selective compartmentalization of ceramide may affect the potency of this signaling molecule in regulating various cellular processes. This is evidenced by differential regulations of cellular autophagy, growth, and viability that are elicited by mitochondrial- and non-mitochondrial-targeting ceramide species. It will be interesting in the future to identify the direct molecular targets of C6-pyridinium ceramide that facilitate the regulation of the above-stated biological processes.

REFERENCES

1. Bartke, N., and Y. A. Hannun. 2009. Bioactive sphingolipids: metabolism and function. J. Lipid Res. 50(Suppl): S91–S96.
2. Ruvolo, P. P. 2005. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 47: 383–392.
3. Zheng, W., J. Kollmeyer, H. Symolon, A. Momin, E. Munter, E. V. Putcha, G. V. Harris, K. L. Moulder, R. M. Easton, C. B. Thompson, and E. M. Johnson, Jr. 2002. Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. J. Cell Biol. 157: 441–453.
4. Perez, D., and E. White. 2000. TNF-α signals apoptosis through a bid-dependent conformational change in the mitochondrial membrane. J. Biol. Chem. 275: 20804–20813.
5. Lucas, S. M., J. Bielawski, A. Bielawska, L. M. Obeid, and A. Bielawska. 2006. Tailoring structure–function and targeting properties of ceramides by site-specific catalytic activities. Mol. Cell. Biol. 144: 891–901.
6. Perez, D., and E. White. 2000. TNF-α signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K. Mol. Cell 6: 53–63.
7. Novgorodov, S. A., Z. M. Szulc, C. Luberto, J. A. Jones, J. Bielawski, A. Bielawska, Y. A. Hannun, and L. M. Obeid. 2005. Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J. Biol. Chem. 280: 16096–16105.
8. Szulc, Z. M., J. Bielawski, H. Gracz, M. Gustilo, N. Mayroo, Y. A. Hannun, L. M. Obeid, and A. Bielawski. 2006. Tailoring structure–function and targeting properties of ceramides by site-specific catalytic activities. Mol. Cell. Biol. 144: 891–901.
tor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. *J. Lipid Res.* **50**:2389–2397.

28. Hsu, Y-T., and R. J. Youle. 1997. Nonionic detergents induce dimerization among members of the Bcl-2 family. *J. Biol. Chem.* **272**:13829–13834.

29. Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. *Cell* **94**:481–490.

30. Gross, A., X. M. Yin, K. Wang, M. C. Wei, J. Jockel, C. Milliman, H. Erdjument-Bromage, P. Tempst, and S. J. Korsmeyer. 1999. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-RI/Fas death. *J. Biol. Chem.* **274**:1156–1163.

31. Antonsson, B., S. Montessuit, B. Sanchez, and J. C. Martinou. 2001. Bax is present as a high molecular weight oligomer-complex in the mitochondrial membrane of apoptotic cells. *J. Biol. Chem.* **276**:11615–11623.

32. Mikhailov, V., M. Mikhailova, D. J. Pulkrabek, Z. Dong, M. A. Venkatachalam, and P. Saikumar. 2001. Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. *J. Biol. Chem.* **276**:18361–18374.

33. Pattineng, S., C. Bauvy, S. Carpentier, T. Levade, B. Levine, and P. Codogno. 2009. Role of JNK-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy. *J. Biol. Chem.* **284**:2719–2728.

34. Li, D. D., L. L. Wang, R. Deng, J. Tang, Y. Shen, J. F. Guo, Y. Wang, L. P. Xia, G. K. Feng, Q. Q. Liu, et al. 2009. The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during cancerous agents-induced autophagy in cancer cells. *Oncogene* **28**:886–898.

35. Dudek, H., S. R. Datta, T. F. Franke, M. J. Birnbaum, R. Yao, G. M. Cooper, R. A. Segal, D. R. Kaplan, and M. E. Greenberg. 1997. Regulation of neuronal survival by the serine-threonine protein kinase Akt. *Science* **275**:661–665.

36. Arico, S., A. Petiot, C. Bauvy, P. F. Dubbelhuis, A. J. Meijer, P. Codogno, and E. Ogier-Denis. 2001. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. *J. Biol. Chem.* **276**:35243–35246.

37. Zhou, H., S. A. Summers, M. J. Birnbaum, and R. N. Pittman. 1998. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. *J. Biol. Chem.* **273**:16568–16575.

38. Schubert, K. M., M. P. Scheid, and V. Duronio. 2000. Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473. *J. Biol. Chem.* **275**:13530–13535.

39. Belaud-Rouneu, M. A., N. Leducq, F. M. P. d. Gannes, P. Diolez, L. Lacoste, F. Lacombe, P. Bernard, and F. Belloe. 2000. Early transitory rise in intracellular pH leads to Bax conformation change during ceramide-induced apoptosis. *Apoptosis* **5**:551–560.

40. von Haefen, C., T. Wieder, B. Gillissen, L. Starck, V. Graupner, B. Dorken, and P. T. Daniel. 2002. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. *Oncogene* **21**:4009–4019.

41. Xin, M., and X. Deng. 2006. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. *J. Biol. Chem.* **281**:18859–18867.

42. Hu, W., R. Xu, G. Zhang, J. Jin, Z. M. Szulc, J. Bidlowski, Y. A. Hannun, L. M. Obeid, and C. Mao. 2005. Golgi fragmentation is associated with ceramide-induced cellular effects. *Med. Biol. Cell* **16**:1555–1567.

43. Phillips, D. C., S. Martin, B. T. Doyle, and J. A. Houghton. 2007. Sphingosine-induced apoptosis in rhabdomyosarcoma cell lines is dependent on pre-mitochondrial Bax activation and post-mitochondrial caspases. *Cancer Res.* **67**:756–764.

44. Nechushtan, A., C. L. Smith, Y-T. Hsu, and R. J. Youle. 1999. Conformation of the Bax C-terminus regulates subcellular location and cell death. *EMBO J.* **18**:2330–2341.

45. Kim, M.Y., C. Linardic, L. Obeid, and Y. Hannun. 1991. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. *J. Biol. Chem.* **266**:484–489.

46. Mathias, S., K. A. Dressler, and R. N. Kolesnick. 1991. Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor alpha. *Proc. Natl. Acad. Sci. U S A* **88**:10009–10013.

47. Heinrich, M., M. Wickel, W. Schneider-Bracht, C. Sandberg, J. Gahr, R. Schwandner, T. Weber, P. Saftig, C. Peters, J. Brunner, M. Kronke, and S. Schütze. 1999. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. *EMBO J.* **18**:5252–5263.

48. Bidere, N., H. K. Lorenzo, S. Carmona, M. Laforge, F. Harper, C. Dumont, and A. Senik. 2003. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. *J. Biol. Chem.* **278**:31425–31431.